

Alessia Campagna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9854601/publications.pdf>

Version: 2024-02-01

14
papers

205
citations

1684188

5
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

356
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	1.6	127
2	Clinical relevance of clonal hematopoiesis in persons aged ≥80 years. <i>Blood</i> , 2021, 138, 2093-2105.	1.4	37
3	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. <i>BMC Cancer</i> , 2019, 19, 50.	2.6	15
4	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. <i>Leukemia Research</i> , 2019, 76, 65-69.	0.8	8
5	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	1.7	6
6	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	2.4	5
7	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 268-271.	2.4	3
8	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3476-3483.	1.3	2
9	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016, 128, 5544-5544.	1.4	1
10	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016, 128, 5465-5465.	1.4	1
11	DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7563-7563.	1.6	0
12	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516.	1.4	0
13	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	1.4	0
14	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical Biological Entity?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2596.	2.4	0